TAFI gene polymorphisms in patients with cerebral venous thrombosis

[1]  G. Stoll,et al.  Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke , 2010, PloS one.

[2]  W. März,et al.  Association between the Thr325Ile polymorphism of the thrombinactivatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study , 2010, Thrombosis and Haemostasis.

[3]  F. Rosendaal,et al.  Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow‐up study , 2010, Journal of thrombosis and haemostasis : JTH.

[4]  M. Roqué,et al.  Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome. , 2009, Thrombosis research.

[5]  D. Radojkovic,et al.  Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. , 2009, Thrombosis research.

[6]  F. Rosendaal,et al.  Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men , 2009, Haematologica.

[7]  J. Deckers,et al.  The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study 1 , 2009, Journal of thrombosis and haemostasis : JTH.

[8]  S. Benlloch,et al.  Association Between the Thr325Ile and Ala147Thr Polymorphisms of the TAFI Gene and the Risk of Venous Thromboembolic Disease , 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[9]  C. Ladenvall,et al.  Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Bird,et al.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis , 2007, Journal of Thrombosis and Thrombolysis.

[11]  F. Rosendaal,et al.  The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI‐antigen levels, clot lysis time and the risk of venous thrombosis , 2006, British journal of haematology.

[12]  A. Grau,et al.  Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems , 2006, Journal of Neurology.

[13]  F. Leebeek,et al.  High functional levels of thrombin‐activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke , 2005, Journal of thrombosis and haemostasis : JTH.

[14]  D. Hendriks,et al.  Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease , 2005, Thrombosis and Haemostasis.

[15]  D. Tregouet,et al.  TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study , 2005, Journal of thrombosis and haemostasis : JTH.

[16]  M. Takeda,et al.  TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction , 2004, British journal of haematology.

[17]  J. De Reuck,et al.  Diabetic ketoacidosis presenting as a cerebral venous sinus thrombosis. , 2004, Acta neurologica Belgica.

[18]  E. Minar,et al.  Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. , 2004, Blood.

[19]  J. Martí-Fàbregas,et al.  Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels , 2003, Stroke.

[20]  C. Molina,et al.  Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke , 2003, Stroke.

[21]  M. Margaglione,et al.  Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[22]  L. Tiret,et al.  Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. , 2001, Blood.

[23]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[24]  M. Bousser.  Cerebral venous thrombosis: diagnosis and management , 1999, Journal of Neurology.

[25]  Y. Tsuda,et al.  Effects of mannitol and glycerol on cerebral energy metabolism in gerbils , 1998, Acta neurologica Scandinavica.

[26]  Z. Odabaşı,et al.  Cerebral venous thrombosis in pregnancy: the role of protein S deficiency. , 1998, Acta neurologica Belgica.

[27]  M. Boffa,et al.  Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties* , 1998, The Journal of Biological Chemistry.

[28]  M. Nesheim,et al.  Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*) , 1995, The Journal of Biological Chemistry.

[29]  D. Drayna,et al.  Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. , 1991, The Journal of biological chemistry.

[30]  J. Wouter Jukema,et al.  Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris , 2003, Thrombosis and Haemostasis.

[31]  M. Prins,et al.  Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. , 2002, Haematologica.

[32]  P. Reitsma,et al.  Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. , 2001, Haematologica.

[33]  R. Lijnen,et al.  Fibrinolysis and thrombolysis , 1986 .

[34]  M. Leroux.  [Fibrinolysis and thrombolysis]. , 1965, Actualites pharmacologiques.